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Cumulative blood lead index  
The calculation of cumulative blood lead index (CBLI) is based on the blood lead level in early 
years of life and the repeated measurement before and after exposure, and the time intervals 
between successive blood lead measurements, which indicates the accumulative level of lead 
exposure.  The formula for CBLI (μg/dL× year) is as follows (1).   
 =  = CBLI 
where Pb_Bi and Pb_Bi+1 are the ith and (i+1)th blood lead levels, and ∆t (in years) is the time 
interval between successive blood lead values (1). In our study, age for workers leaving school at 
less than, at, and above the 12th grade were assumed to be 14, 18 and 23 years; based on 
NHANES data (1988-1994), the corresponding blood lead levels in early years were set at 2.2, 
1.4 and 1.5 µg/dL, respectively (2).  Therefore, the CBLI in our study was:  
CBLI = 0.5 × (A0-Ae) × (Pb0+Pbe) + 0.5 × (A1-A0) × (Pb1+Pb0) + 0.5 × (A2-A1) × (Pb2+Pb1)  
The symbols, e, 0, 1 and 2 in the equation above, represented the age (A) and blood lead level 
(Pb) early in life, at baseline, and at the 1-year and 2-year follow-up visits, respectively.  If the 
participant missed one follow-up visit, the last term of the above equation was dropped.   
References  
1.  Roels H, Konings J, Green S, Bradley D, Chettle D, Lauwerys R. Time-integrated blood lead 
concentration is a valid surrugate for estimating the cumulative lead dose assessed by tibial 
lead measurement. Environ Res. 1995;69:75-82.  
2.  Fadrowski JJ, Navas-Acien A, Tellez-Plaza M, Guallar E, Weaver VM, Furth SL. Blood lead 
level and kidney function in US adolescents. The Third National Health ans Nutrition 
Examination Survey. Arch Intern Med. 2010;170:75-82.  
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Table S1.   Baseline and follow-up characteristics of workers in the DST cohort (starts).  Averge values are arithmetic [standard deviation (SD)] or 
geometric means [interquartile range (IR)]. [CI=confidence interval; HDL=high density lipoprotein; DST=digit-symbol test].   
Characteristic (N=260)  
Baseline   Last follow-up   ∆ (95% CI)a   
P value  
N (%)  Mean (SD/IR)   N (%)  Mean (SD/IR)   Mean  95% CI   
Education            
Less than high school  9 (3.46)    9 (3.46)        
High school or equivalent  205 (78.8)    205 (78.8)        
College or university  46 (17.7)    46 (17.7)        
Alcohol intakeb            
Non-drinkers  147 (56.5)    110 (42.3)    -14.2  -20.4, -7.87   
0.0047  
Light  74 (28.5)    84 (32.3)    3.85  -3.10, 10.7   
Moderate  25 (9.62)    44 (16.9)    7.31  2.31, 12.2   
Heavy  14 (5.38)    22 (8.46)    3.08  -1.03, 7.13   
Current smokers  69 (26.5)    72 (27.7)    1.15  -2.90, 5.17   0.58  
Hypertension ≥ stage 1c  128 (49.2)    165 (63.5)    14.2  6.65, 21.6   0.0002  
Hypertension ≥ stage 2c  45 (17.3)    45 (17.3)    --  --   --  
Treated hypertension  14 (5.38)    25 (9.62)    4.23  1.55, 6.85   0.0019  
Diabetes mellitusd  10 (3.85)    16 (6.15)    2.31  0.19, 4.39   0.032  
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Table S1.   Baseline and follow-up characteristics of workers in the DST cohort (continued from page 3).  Average values are arithmetic [standard 
deviation (SD)] or geometric means [interquartile range (IR)]. [CI=confidence interval; HDL=high density lipoprotein; DST=digit-symbol test].   
Characteristic (N=260)  
Baseline   Last follow-up   ∆ (95% CI)a   
P value  
N (%)  Mean (SD/IR)   N (%)  Mean (SD/IR)   Mean  CI   
Age, years   29.4 (9.68)    31.2 (9.75)   1.82  1.76, 1.87   <0.0001  
Systolic pressure (mm Hg)c   120.1 (10.5)    123.0 (9.67)   2.97  1.66, 4.29  <0.0001  
Diastolic pressure (mm Hg)c   79.6 (8.93)    80.8 (7.44)   1.22  0.09, 2.36   0.035  
Heart rate (beats/minute)c   74.3 (11.8)    79.0 (11.1)   4.73  3.05, 6.42  <0.0001 
Body mass index (kg/m2)e   28.8 (6.04)    29.4 (6.10)   0.62  0.36, 0.89   <0.0001  
Serum creatinine (mg/dL)f    0.93 (0.23)    1.01 (0.18)   0.08  0.06, 0.10   <0.0001  
Total serum cholesterol (mg/dL)f   171.8 (38.4)    174.5 (37.3)   2.59  -0.33, 5.50   0.082  
HDL serum cholesterol (mg/dL)f   46.8 (12.4)    46.2 (11.7)   -0.55  -1.61, 0.51   0.31  
Total-to-HDL cholesterol ratio   3.90 (1.30)    4.02 (1.40)   0.12  0.01, 0.22   0.033  
Blood glucose (mmol/L)f   93.8 (15.6)    91.3 (34.9)   -2.24  -6.79, 2.31   0.33  
Blood lead (µg/dL, log)f    3.97 (2.30-7.70)    13.1 (9.45-22.1)   230  195, 270   <0.0001  
a Changes from baseline to last follow-up are given with 95% confidence interval.  For proportions, categorical variables and logarithmically transformed variables, 
percentage changes are given.   
b Participants were categorized as non-drinker versus light, moderate or heavy drinkers.  Among women, light, moderate and heavy drinkers reported a daily alcohol intake 
of ≤6, >6-14 and >14 gram; for men, these quantities were ≤12, >12-28, and >28 gram, respectively.   
c Blood pressure was the average of five consecutive readings obtained with the auscultatory technique after the workers had rested for 5 minutes in the seated position.  
Hypertension was categorized according to the 2017 ACC/AHA guideline, irrespective of treatment status.  If systolic and diastolic blood pressures were in different 
categories, the highest level was used to classify participants.  Stage-1 hypertension was a blood pressure of 130-139 mm Hg systolic and 80-89 mm Hg diastolic.  Higher 
levels were classified as stage 2.  Heart rate was counted over 15 s.   
d Diabetes mellitus was a self-reported diagnosis, a fasting blood glucose of 126 mg/dL (7 mmol/L) or higher, or use of antidiabetic drugs.   
e Body mass index is weight in kilograms divided by height in meter squared.   
f To convert serum creatinine to µmol/L, multiply by 88.42; to convert cholesterol to mmol/L, multiply by 38.67; to convert glucose to mg/dL, multiply by 17.9; to convert lead 
from µg/dL to µmol/L multiply by 20.   
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Table S2.   Baseline and follow-up characteristics of workers in the ST cohort (starts).  Average values are arithmetic [standard deviation (SD)] or 
geometric means [interquartile range (IR)]. [CI=confidence interval; HDL=high density lipoprotein; ST=Stroop test].   
Characteristic (N=168)   
Baseline   Last follow-up    ∆ (95% CI)a   
P value  
N (%)  Mean (SD/IR)   N (%)  Mean (SD/IR)   Mean  CI   
Education            
Less than high school  7 (4.17)    7 (4.17)        
High school or equivalent  130 (77.4)    130 (77.4)        
College or university  31 (18.5)    31 (18.5)        
Alcohol intakeb            
Non-drinkers  95 (56.5)    72 (42.9)    -13.7  -21.7, -5.39   
0.067  
Light  49 (29.2)    61 (36.3)    7.14  -1.30, 15.5   
Moderate  14 (8.33)    24 (14.3)    5.95  -0.15, 11.9   
Heavy  10 (5.95)    11 (6.55)    0.60  -4.16, 5.34   
Current smokers  47 (28.0)    52 (31.0)    2.98  -2.60, 8.45   0.30  
Hypertension ≥ stage 1c  80 (47.6)    118 (70.2)    22.6  13.9, 30.8   <0.0001  
Hypertension ≥ stage 2c  30 (17.9)    36 (21.4)    3.57  -2.30, 9.38   0.24  
Treated hypertension  10 (5.95)    14 (8.33)    2.38  -0.45, 5.15   0.10  
Diabetes mellitusd  6 (3.57)    7 (4.17)    0.60  -1.40, 2.58   0.56  
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Table S2.   Baseline and follow-up characteristics of workers in the ST cohort (continued from page 5).  Average values are arithmetic [standard 
deviation (SD)] or geometric means [interquartile range (IR)]. [CI=confidence interval; HDL=high density lipoprotein; ST=Stroop test].   
Characteristic (N=168)   
Baseline   Last follow-up    ∆ (95% CI)a   
P value  
N (%)  Mean (SD/IR)   N (%)  Mean (SD/IR)   Mean  95% CI   
Age, years   29.7 (9.68)    30.8 (9.96)   1.10  0.72, 1.49   <0.0001  
Systolic pressure (mm Hg)c   119.4 (10.3)    123.4 (9.30)   4.01  2.50, 5.53   <0.0001  
Diastolic pressure (mm Hg)c   79.6 (9.10)    82.9 (7.27)  3.27 1.85, 4.69  <0.0001  
Heart rate (beats/minute)c   74.8 (12.3)    80.0 (12.0)  5.17 3.25, 7.09  <0.0001  
Body mass index (kg/m2)e   28.6 (5.59)    28.9 (5.55)   0.25  0.03, 0.46   0.026  
Serum creatinine (mg/dL)f    0.94 (0.17)    1.00 (0.17)   0.06  0.04, 0.08   <0.0001  
Total serum cholesterol (mg/dL)f   173.7 (34.0)    172.0 (35.9)   -1.68  -5.14, 1.78   0.34  
HDL serum cholesterol (mg/dL)f   46.5 (12.0)    45.3 (11.7)   -1.25  -2.53, 0.02   0.055  
Total-to-HDL cholesterol ratio   3.94 (1.14)    4.03 (1.31)   0.10  -0.03, 0.22   0.12  
Blood glucose (mmol/L)f   93.8 (16.3)    87.3 (31.9)   -6.48  -11.8, -1.16   0.017  
Blood lead (µg/dL, log)f    4.13 (2.30-7.80)    14.2 (10.9-21.3)   244  203, 291   <0.0001  
a Changes from baseline to last follow-up are given with 95% confidence interval.  For proportions, categorical variables and logarithmically transformed variables, 
percentage changes are given.   
b Participants were categorized as non-drinker versus light, moderate or heavy drinkers.  Among women, light, moderate and heavy drinkers reported a daily alcohol 
intake of ≤6, >6-14 and >14 gram; for men, these quantities were ≤12, >12-28, and >28 gram, respectively.   
c Blood pressure was the average of five consecutive readings obtained with the auscultatory technique after the workers had rested for 5 minutes in the seated 
position.  Hypertension was categorized according to the 2017 ACC/AHA guideline, irrespective of treatment status.  If systolic and diastolic blood pressures were 
in different categories, the highest level was used to classify participants.  Stage 1 hypertension was a blood pressure of 130-139 mm Hg systolic and 80-89 mm 
Hg diastolic.  Higher levels were classified as stage 2.  Heart rate was counted over 15 s.  
d Diabetes mellitus was a self-reported diagnosis, a fasting blood glucose of 126 mg/dL (7 mmol/L) or higher, or use of antidiabetic drugs.   
e Body mass index is weight in kilograms divided by height in meter squared.   
f To convert serum creatinine to µmol/L, multiply by 88.42; to convert cholesterol to mmol/L, multiply by 38.67; to convert glucose to mg/dL, multiply by 17.9; to 
convert lead from µg/dL to µmol/L multiply by 20.   
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Table S3.  Baseline characteristics of workers analyzed and not analyzed (starts).  Average values are arithmetic [standard deviation 
(SD)] or geometric means [interquartile range (IR)]. [CI=confidence interval; HDL=high density lipoprotein].   
Characteristic  
Analyzed (N=267)   Not analyzed (N=239)    
P value 
N (%)  Mean (SD/IR)  N (%)  Mean (SD/IR)   
Education        
Less than high school  9 (3.4)    6 (2.5)    
0.61  High school or equal  211 (79.0)    190 (79.5)    
College or university  47 (17.6)    43 (18.0)    
Alcohol consumptiona         
Non-drinkers  150 (56.2)    146 (61.1)    
0.72  
Light  77 (28.8)    63 (26.4)    
Moderate  25 (9.36)    19 (7.95)    
Heavy  15 (5.62)    11 (4.60)    
Current smokers  71 (26.6)    73 (30.5)    0.33  
Hypertension > stage 1b  132 (49.4)    155 (64.9)    0.0005  
Hypertension ≥ stage 2b  47 (17.6)    40 (16.7)    0.80  
Treated hypertensionb  14 (5.24)    11 (4.60)    0.74  
Diabetes mellitusc  10 (3.75)    6 (2.51)    0.43  
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Table S3.  Baseline characteristics of workers analyzed and not analyzed (continued from page 7).  Average values are arithmetic 
[standard deviation (SD)] or geometric means [interquartile range (IR)]. [CI=confidence interval; HDL=high density lipoprotein].   
Characteristic  
Analyzed (N=267)   Not analyzed (N=239)    
P value 
N (%)  Mean (SD/IR)   N (%)  Mean (SD/IR)   
Age, years   29.5 (9.78)    27.9 (10.1)   0.085  
Systolic pressure (mm Hg)b   120.1 (10.5)    120.2 (10.2)   0.90  
Diastolic pressure (mm Hg)b   79.6 (8.90)    81.2 (8.24)   0.037  
Heart rate (beats/minute)b   74.3 (11.9)    74.9 (12.5)   0.59  
Body mass index (kg/m2)d   28.7 (6.02)    29.2 (6.84)   0.37  
Serum creatinine (md/dL)e    0.93 (0.23)    0.95 (0.17)   0.83  
Total serum cholesterol (mg/dL)e   172.0 (38.1)    171.5 (38.4)   0.95  
HDL serum cholesterol (mg/dL)e   46.9 (12.3)    47.4 (12.0)   0.58  
Total-to-HDL cholesterol ratio   3.89 (1.29)    3.85 (1.35)   0.80  
Blood glucose (mg/dL)e   93.8 (15.4)    93.2 (11.9)   0.33  
Blood lead (µg/dL, log)e   4.04 (2.30-7.80)    4.14 (2.30-7.80)   0.74  
a Participants were categorized as non-drinker versus light, moderate and heavy drinkers.  Among women, light, moderate and heavy drinkers 
reported a daily alcohol intake of ≤6, >6-14 and >14 gram; for men, these quantities were ≤12, >12-28, and >28 gram, respectively.   
b Blood pressure was the average of five consecutive readings obtained with the auscultatory technique after the workers had rested for 5 minutes in 
the seated position.  Hypertension was categorized according to the 2017 ACC/AHA guideline, irrespective of treatment status.  If systolic and 
diastolic blood pressures were in different categories, the highest level was used to classify participants.  Stage 1 hypertension was a blood pressure 
of 130-139 mm Hg systolic and 80-89 mm Hg diastolic.  Higher levels were classified as stage 2.  Heart rate was counted over 15 s.  
c Diabetes mellitus was a self-reported diagnosis, a fasting blood glucose of 126 mg/dL (7 mmol/L) or higher, or use of antidiabetic drugs.   
d Body mass index is weight in kilograms divided by height in meter squared.  
e To convert serum creatinine to µmol/L, multiply by 88.42; to convert cholesterol to mmol/L, multiply by 38.67; to convert glucose to mg/dL, multiply 
by 17.9; to convert lead from µg/dL to µmol/L multiply by 20.    
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Table S4.  Baseline neurocognitive function by fourths of the distribution of the follow-up-to-baseline blood lead concentration ratio (starts).  Average values 
are geometric means [interquartile range (IR)]. [MRT=mean reaction time; DST=digit-symbol test; ST=Stroop test].   
Characteristic  
Low fourth   Low-middle fourth   High-middle fourth   High fourth  P for  
linear 
trenda  N/Mean  %/IR   N/Mean  %/IR   N/Mean  %/IR  N/Mean  %/IR  
DST cohort (N=260)              
Quartile limits  <1.90   1.90-3.37   3.37-5.75   ≥5.75   
Mean latency time (s, log)  112.8  97.5-130.5  109.8  96.0-120.8   105.9  97.6-116.1   107.2  92.8-119.1  0.076  
Number of errors              
0  33  50.8   37  56.9   43  66.2   40  61.5  
0.10  1  21  32.3   17  26.2   18  27.7   17  26.2  
>1  11  16.9   11  16.9   4  6.2   8  12.3  
ST cohort (N=168)                
Quartile limits  <1.98   1.98-3.26   3.26-5.52   ≥5.52    
MRT in incongruent trials (ms, log)               
All responses  1636  1321-1965   1552  1238-1841   1574  1348-1837   1664  1356-2006      0.75  
Correct responsesa   1638  1321-1965   1559  1238-1876   1572  1373-1837   1666  1356-2047      0.78  
MRT congruent trials (ms, log)               
All responses  1495  1187-1815   1390  1163-1492   1565  1195-1920   1496  1179-1680      0.61  
Correct responsesa   1495  1187-1815   1390  1163-1492   1565  1195-1920   1496  1179-1680      0.61  
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Table S4.  Baseline neurocognitive function by fourths of the follow-up-to-baseline blood lead concentration ratio (continued from page 9).  Average values 
are geometric means [interquartile range (IR)]. [MRT=mean reaction time; DST=digit-symbol test; ST=Stroop test].   
Characteristic  
Low fourth   Low-middle fourth   High-middle fourth   High quartile  P for  
linear 
trenda  N/Mean %/IR   N/Mean %/IR   N/Mean %/IR  N/Mean  %/IR  
Correct ratio in incongruent trials (%)                
100  37  88.1   37  88.1   34  81.0   37  88.1  
0.40  90-99    3    7.1     2    4.8     4    9.5     3    7.1  
<90    2    4.8     3    7.1     4    9.5     2    4.8  
Correct ratio in congruent trials (%)                
100  42  100   42  100   42  100   42  100  
1.00  
<100  0  0   0  0   0  0   0  0  
Interference effect (ms, log)               
All responses  1.09  0.96-1.21   1.12  0.97-1.27   1.01  0.94-1.15   1.11  0.99-1.29  
0.77  
Correct responsesb  1.10 0.97-1.22   1.12  0.98-1.27   1.00  0.94-1.15   1.12  0.99-1.19  
Interference score               
>0    0  0.0     0  0.0     0  0.0     0  0.0  
0.76  0  37  88.1   37  88.1   34  81.0   37  88.1  
>0    5  11.9     5  11.9     8  19.0     5  11.9  
a There was no bias in the initial values of the neurocognitive tests across increasing categories of the follow-up-to-baseline blood lead concentration ratio.   
b One participant did not provide any correct response at baseline and follow-up and was not included in the MRT of correct responses.   
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Table S5 Follow-up neurocognitive function by fourths of the distribution of the follow-up-to-baseline blood lead concentration ratio (starts).  Average values 
are geometric means [interquartile range (IR)]. [MRT=mean reaction time; DST=digit-symbol test; ST=Stroop test].  
Characteristic  
Low fourth   Low-middle fourth   High-middle fourth   High fourth  P for  
linear  
trenda  N/Mean %/IR   N/Mean %/IR   N/Mean %/IR  N/Mean  %/IR  
DST cohort (N=260)                 
Quartile limits  <1.90   1.90-3.37   3.37-5.75   ≥5.75   
Mean latency time (s, log)  104.8  90.8-117.9  111.6  95.5-127.7   105.6  88.7‒121.2   108.6  91.3-126.8  0.65  
Number of errors               
0  38  58.5   40  61.5   39  60.0   43  66.2  
0.38  1  19  29.2   18  27.7   16  24.6   18  27.7  
>1    8  12.3     7  10.8   10  15.4     4    6.2 
ST cohort (N=168)               
Quartile limits  <1.98   1.98-3.26   3.26-5.52   ≥5.52   
MRT in incongruent trials (ms, log)              
All responses  2287  1910-2901   2094  1664-2575   2105  1667-2630   1886  1558-2227     0.016  
Correct responsesa   2260  1910-2895   2110  1733-2575   2127  1667-2630  1832  1517-2146    0.0093  
MRT congruent trials (ms, log)              
All responses  2237 1854-2763   1883  1501-2535   1935  1539-2248   1882  1539-2099    0.050  
Correct responsesa   2237 1854-2763   1903  1501-2604   1935  1539-2248   1904  1603-2099      0.061  
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Table S5  Follow-up neurocognitive function by fourths of the distribution of the blood lead changes (continued from page 11).  Average values are 
geometric means [interquartile range (IR)]. [MRT=mean reaction time; DST=digit-symbol test; ST=Stroop test].  
Characteristic  
Low fourth   Low-middle fourth   High-middle fourth   High fourth  P for  
linear  
trenda  N/Mean %/IR   N/Mean %/IR   N/Mean %/IR  N/Mean  %/IR  
Correct ratio in incongruent trials (%)               
100  34  81.0   33  78.6   34  81.0   37  88.1  
0.10  90-99    6  14.3     5  11.9     4    9.5     2   4.8  
<90    2    4.8     4    9.5     4    9.5     3   7.1  
Correct ratio in congruent trials (%)               
100  42  100   40  95.2   42  100   40  95.2  
0.44  
<100  0  0   2    4.8   0   0   2    4.8  
Interference effect (ms, log)               
All responses  1.02  0.88-1.17   1.11  0.93-1.22   1.09  0.93-1.27   1.00  0.85-1.23  0.63  
Correct responsesb   1.02  0.89-1.13   1.10  0.90-1.19   1.10  0.93-1.34   0.98  0.84-1.15  0.52  
Interference score               
>0  0  0.0   2  4.8   0  0.0   1  2.4  
0.40  0  34  81.0   32  76.2   34  81.0   36  85.7  
>0  8  19.0   8  19.0   8  19.0   5  11.9  
a There was no gradient at follow-up in the neurocognitive tests results across increasing categories of the follow-up-to-baseline blood lead concentration ratio.  
b One participant did not provide any correct response at baseline and follow-up and was not included in the MRT of correct responses.   
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Table S6.  Associations between changes (∆) from baseline to follow-up in neurocognitive function and blood lead stratified by the median baseline age.  
[OR=odds ratio; CI=95% confidence interval; DST=digit-symbol test; ST=Stroop test; MRT=mean reaction time].   
Characteristic  
 Stratified by the median baseline age   
P for interaction  
 %a  ORa  CI  P value   %a  ORa  CI  P value   
DST cohort (N=260)               
Age   <26.4 years (N=130)   ≥26.4 years (N=130)    
∆ latency time (%)   0.33   -1.04, 1.71  0.64   0.58   -0.65, 1.82  0.35   0.20  
Increasing error rate (0,1)    1.14  0.69, 1.89  0.60    1.46  0.89, 2.62  0.13   0.59  
ST cohort (N=168)               
Age   <27.0 years (N=84)   ≥27.0 years (N=84)    
∆ MRT in incongruent trials              
All responses (%)   1.90   -2.29, 6.25  0.35   -2.58   -5.71, -0.66  0.11   0.57  
Correct responses (%)   0.68   -3.24, 4.76  0.72   -2.52   -5.79, 0.86  0.13   0.98  
∆ MRT in congruent trials              
All responses (%)   -0.19   -4.72, 4.56 0.93   -1.88   -5.82, 2.23  0.34   0.92  
Correct responses (%)   -0.13   -4.71, 4.68 0.95   -1.98   -5.84, 2.04  0.31   0.83  
Increasing error rate              
Incongruent trials (0,1)b    …  …  …    …  …   …   …  
Congruent trials (0,1)b    …  …  …    …  …  …   …  
∆ Interference effect              
All responses (%)   2.33   -1.03, 5.80  0.16   -0.53   -3.54, 2.56  0.72   0.42  
Correct responses (%)   1.91   -1.44, 5.38  0.25   -0.23   -3.41, 3.06  0.88   0.56  
a For continuous outcomes, estimates express the percentage difference in the follow-up to baseline ratio of DST latency/ST mean reaction time associated with a doubling 
in the follow-up-to-baseline blood lead concentration ratio.  For categorical outcomes, estimates are odds ratios (OR) associating the probability that workers had increasing 
error rates with a doubling in the follow-up-to-baseline blood lead concentration ratio.  Estimates were derived from mixed models, including both the 1-year and 2-year 
changes in neurocognitive function and blood lead, and accounting for the within-subject correlations using a random participant effect.  Adjustments were made for sex, 
baseline age, the baseline neurocognitive test result, ethnicity (white vs other), change in age, baseline body mass index, change in body weight, educational attainment, 
baseline blood lead, and the baseline values of and changes during follow-up in smoking status, alcohol consumption (light, moderate and heavy drinkers), and the total-to-
HDL serum cholesterol ratio.   
b An ellipsis indicates that the model did not converge.   
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Table S7.  Associations between changes (∆) from baseline to follow-up in neurocognitive function and blood lead stratified by the median baseline blood 
lead concentration [OR=odds ratio; CI=95% confidence interval; DST=digit-symbol test; ST=Stroop test; MRT=mean reaction time].   
Characteristic  
 Stratified by the median baseline blood lead   
P for interaction 
 %a ORa CI  P value   %a ORa CI  P value   
DST cohort (N=260)               
Baseline blood lead   <4.20 µg/dL (N=126)   ≥4.20 µg/dL (N=134)    
∆ latency time (%)   -0.09   -1.22, 1.06  0.88   1.19   -0.29, 2.68  0.11   0.27  
Increasing error rate (0,1)    1.00  0.64, 1.58  0.99    1.68  0.99, 2.86   0.056   0.34  
ST cohort (N=168)               
Baseline blood lead   <4.30 µg/dL (N=81)   ≥4.30 µg/dL (N=87)    
∆ MRT in incongruent trials              
All responses (%)   -1.90   -5.52, 1.86  0.29   1.16   -3.04, 5.53  0.57   0.70  
Correct responses (%)   -2.84   -6.16, 0.60  0.096   1.34   -3.08, 5.96  0.54   0.45  
∆ MRT in congruent trials              
All responses (%)   -1.70   -5.66, 2.41 0.38    0.12   -5.20, 5.73  0.96   0.65  
Correct responses (%)   -1.66   -5.54, 2.39 0.38    0.36   -5.03, 6.05  0.89   0.64  
Increasing error rate              
Incongruent trials (0,1)b    …  …  …    …  …  …   …  
Congruent trials (0,1)b     …  …  …    …  …  …   …  
∆ Interference effect              
All responses (%)   0.18   -2.47, 2.91  0.88   1.44   -2.67, 5.73  0.47   0.34  
Correct responses (%)   -0.18   -2.78, 2.49  0.89   1.55   -2.72, 6.01  0.46   0.22  
a For continuous outcomes, estimates express the percentage difference in the follow-up to baseline ratio of DST latency/ST mean reaction time associated with a doubling 
in the follow-up-to-baseline blood lead concentration ratio.  For categorical outcomes, estimates are odds ratios (OR) associating the probability that workers had 
increasing error rates with a doubling in the follow-up-to-baseline blood lead concentration ratio.  Estimates were derived from mixed models, including both the 1-year 
and 2-year changes in neurocognitive function and blood lead, and accounting for within-subject correlations using a random participant effect.  Adjustments were made 
for sex, baseline age, the baseline neurocognitive test result, ethnicity (white vs other), change in age, baseline body mass index, changes in body weight, educational 
attainment, baseline blood lead, and the baseline values of and changes during follow-up in smoking status, alcohol consumption (light, moderate and heavy drinkers), 
and the total-to-HDL serum cholesterol ratio.   
b An ellipsis indicates that the model did not converge.    
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Table S8.  Associations between changes (∆) from baseline to follow-up in neurocognitive function and blood lead stratified by the median CBLI [OR=odds 
ratio; CI=95% confidence interval; DST=digit-symbol test; ST=Stroop test; MRT=mean reaction time; CBLI=cumulative blood lead index].   
Characteristic  
 Stratified by the median of CBLI   
P for interaction 
 %a ORa CI  P value   %a ORa CI  P value   
DST cohort (N=260)               
CBLI   <32.5 µg/dL × year (N=130)   ≥32.5 µg/dL × year (N=130)    
∆ latency time (%)   0.57   -0.56, 1.72  0.32   -0.06   -1.53, 1.43  0.93   0.21  
Increasing error rate (0,1)    1.10  0.66, 1.83  0.72    1.23   0.75, 2.00   0.41   0.87  
ST cohort (N=168)               
CBLI   <33.3 µg/dL × year (N=84)   ≥33.3 µg/dL × year (N=84)    
∆ MRT in incongruent trials              
All responses (%)   -0.27   -3.86, 3.46  0.88   -3.12   -6.92, 0.84  0.11   0.57  
Correct responses (%)   -1.07   -4.38, 2.35  0.51   -2.80   -6.70, 1.27  0.16   0.83  
∆ MRT in congruent trials              
All responses (%)   -0.38   -4.50, 3.91  0.85   -3.80   -8.43, 1.06  0.11   0.69  
Correct responses (%)   -0.28   -4.34, 3.96  0.89   -3.75   -8.43, 1.16  0.12   0.64  
Increasing error rate              
Incongruent trials (0,1)b    …  …  …    …  …  …   …  
Congruent trials (0,1)b     …  …  …    …  …  …   …  
∆ Interference effect              
All responses (%)   0.06   -2.71, 2.91  0.96   1.22   -2.66, 5.24  0.52   0.93  
Correct responses (%)   -0.24   -2.91, 2.51  0.85   1.81   -2.20, 5.99  0.36   0.73  
a For continuous outcomes, estimates express the percentage difference in the follow-up to baseline ratio of DST latency/ST mean reaction time associated with a doubling 
in the follow-up-to-baseline blood lead ratio.  For categorical outcomes, estimates are odds ratios (OR) associating the probability that workers had increasing error rates 
with a doubling in the follow-up-to-baseline blood lead ratio.  Estimates were derived from mixed models, including both the 1-year and 2-year changes in neurocognitive 
function and blood lead, and accounting for within-subject correlations using a random participant effect.  Adjustments were made for sex, baseline age, the baseline 
neurocognitive test result, ethnicity (white vs other), change in age, baseline body mass index, change in body weight, educational attainment, baseline blood lead, and 
the baseline values of and changes during follow-up in smoking status, alcohol consumption (light, moderate and heavy drinkers), and the total-to-HDL serum cholesterol 
ratio.   
b An ellipsis indicates that the model did not converge.    
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Table S9.  Associations between changes in neurocognitive function (∆) and blood lead from baseline to follow-up modelled by linear 
regression. [CI=95% confidence interval; DST=digit-symbol test; ST=Stroop test; MRT=mean reaction time].  
Characteristic  
 Unadjusted   Adjusteda   Fully adjustedb  
 % c CI  P value   % c CI  P value   % c CI  P value  
DST cohort              
1-year follow-up (N=244)               
∆ latency time (%)   0.49  -0.30, 1.29  0.23   0.13  -0.53, 0.80  0.69   -0.08  -1.06, 0.90  0.87  
2-year follow-up (N=203)               
∆ latency time (%)   1.72  0.62, 2.84  0.0025   0.97  0.03, 1.92  0.044   1.37  0.05, 2.71  0.043  
ST cohort d              
1-year follow-up (N=168)               
∆ MRT in incongruent trials   -2.15  -3.95, -0.31  0.023   -1.96  -3.48, -0.42  0.014   -1.07  -3.47, 1.38  0.39  
∆ MRT in congruent trials   -1.24  -3.47, 1.03 0.28   -1.19  -2.94, 0.58  0.19   -1.93  -4.66, 0.88  0.18  
∆ Interference effect   -0.92  -2.67, 0.87  0.31   -0.72  -2.08, 0.67  0.31   1.31  -0.88, 3.55  0.24  
a Adjusted models accounted for sex and baseline age and the baseline neurocognitive test results, i.e., latency/reaction time (continuous outcomes) or the 
number of errors (ordinal outcomes).   
b Fully adjusted models additionally accounted for ethnicity (white vs other), change in age, baseline body mass index, change in body weight, educational 
attainment, baseline blood lead, and the baseline values of and changes during follow-up in smoking status, the total-to-HDL serum cholesterol ratio, and 
alcohol intake (light, moderate and heavy).   
c All association sizes are expressed for a doubling in the follow-up-to-baseline blood lead concentration ratio.  Estimates are the percentage difference in the 
follow-up minus baseline value for continuous variables and odds ratios for categorical outcomes.   
d Only 48 participants had a follow-up visit at the second year.    
e An ellipsis indicates that the model did not converge.   
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Table S10.  Association of neurocognitive function with blood lead at baseline and last follow-up analysed separately, using linear of logistic regression.  
[CI=95% confidence interval; MRT=mean reaction time; BL=baseline; FU=last follow-up; Pslope=significance of the difference between baseline and 
follow-up in the slope of the neurocognitive measurement on the blood lead concentration]   
Characteristics   Unadjusteda   Adjusteda  
Stroop test   β  95% CI  P-value  Pslope   β  95% CI  P-Value  Pslope  
MRT of incongruent trials (ms, log) BL  1.53 -4.29, 7.71 0.61 
0.92 
 1.66 -4.27, 7.95 0.59 
0.57 
 FU  1.00 -7.56, 10.4 0.83  4.97 -4.30, 15.1 0.31 
MRT of congruent trials (ms, log) BL  0.80 -5.79, 7.84 0.82 
0.67 
 0.71 -6.02, 7.92 0.84 
0.88 
 FU  -1.70 -10.5, 7.92 0.72  1.67 -8.16, 12.6 0.75 
Interference effect  BL  0.73 -3.64, 5.30 0.75 
0.61 
 0.94 -3.53, 5.62 0.69 
0.59 
 FU  2.75 -3.50, 9.40 0.40  3.25 -3.58, 10.6 0.36 
Digit-symbol test   β  95% CI  P-value  Pslope   β  95% CI  P-Value  Pslope  
Latency time (s, log)  BL  0.38 -2.47, 3.31 0.80 
0.47 
 1.04 -1.82, 3.98 0.48 
0.75 
 FU  2.10 -1.47, 5.81 0.25  1.85 -2.03, 5.88 0.36 
Stroop Test   OR  95% CI  P-Value  Pslope   OR  95% CI  P-Value  Pslope  
Error score in incongruent trials  BL  1.53 0.41, 5.69 0.53 
0.34 
 1.35 0.32, 0.55 0.68 
0.32 
 FU  0.60 0.15, 2.45 0.48  0.46 0.10, 2.16 0.33 
Interference score BL  0.65 0.18, 2.43 0.53 
0.28 
 0.74 0.18, 3.07 0.68 
0.28 
 FU  1.88 0.46, 7.71 0.38  2.36 0.50, 11.2 0.28 
Digit-symbol test   OR  95% CI  P-Value  Pslope   OR  95% CI  P-Value  Pslope  
Error score  BL  0.93 0.47, 1.81 0.82 
0.33 
 0.97 0.48, 1.98 0.94 
0.23 
 FU  1.56 0.70, 3.48 0.28  2.00 0.80, 5.00 0.14 
a All models were derived by linear or logistic regression analysis for continuous and categorical outcomes, respectively.  Adjusted models accounted for sex, age, 
ethnicity (white vs other), body mass index, educational attainment, current smoking, alcohol intake (light, moderate and heavy), and the total-to-HDL serum cholesterol 
ratio.  Associatiion sizes were expressed for a 10-fold difference in the blood lead concentration at baseline or follow-up.   
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Table S11.  Time-dependent DST and ST results by observer (starts).  Average values are geometric means [interquartile range (IR)]. [MRT=mean 
reaction time; DST=digit-symbol test; ST=Stroop test].   
Characteristica   
Overall   Baseline   Year 1   Year 2  
Nb Mean IR  Nb Mean IR  Nb Mean IR  Nb Mean IR 
DST cohort (N=260)                 
Mean latency time (s, log)c                
Observer 1      6 99.1 84.4-111.8  6 99.1 84.4-111.8  0 … …  0 … … 
Observer 2     57 101.1 89.9-114.4  53 101.8 91.6-114.4  2 106.3 89.2-126.8  2 79.6 64.2-98.6 
Observer 3    72 104.1 93.6-117.4  69 104.6 94.4-117.3  3 93.3 77.8-118.0  0 … … 
Observer 4   99 108.0 91.8-122.3  0 … …  39 115.5 102.1-130.0  60 103.4 88.1-115.8 
Observer 5   118 111.5 93.0-131.9  0 … …  40 119.3 107.0-133.6  78 107.6 90.0-125.9 
Observer 6   40 112.0 97.6-124.8  28 109.5 95.1-121.6  12 118.0 108.3-131.8  0 … … 
Observer 7   75 112.1 100.8-122.7  41 107.7 95.6-119.9  34 117.6 108.6-123.4  0 … … 
Observer 8   7 112.6 87.7-131.3  3 120.6 85.3-156.5  4 107.0 93.9-121.9  0 … … 
Observer 9    148 115.7 102.7-130.2  37 120.6 107.4-131.2  70 117.7 105.7-131.5  41 108.3 91.3-120.3 
Observer 10     85 116.9 101.8-133.5  23 124.5 104.8-149.8  40 119.3 107.0-133.6  22 105.4 91.3-125.8 
ST cohort (N=168)                 
MRT in incongruent trials (ms, log)c                
Observer 1      5 1344 1294-1499  5 1344 1294-1499  0 … …  0 … … 
Observer 2     5 1426 1146-1440  1 1225 …  4 1481 1129-1942  0 … … 
Observer 3    52 1471 1216-1734  49 1468 1235-1725  3 1515 1089-2450  0 … … 
Observer 4     39 1659 1288-1998  37 1678 1307-1998  2 1346 1051-1724  0 … … 
Observer 5    31 1693 1321-2081  21 1466 1210-1842  10 2291 2014-2533  0 … … 
Observer 6    78 1714 1410-2014  40 1695 1371-1946  38 1734 1425-2150  0 … … 
Observer 7    32 1926 1608-2250  0 … …  28 1855 1516-2116  4 2504 2069-3030 
Observer 8    87 2100 1667-2535  15 2049 1513-2678  63 2104 1672-2516  9 2155 1736-2630 
Observer 9    17 2154 1919-2478  0 … …  8 2012 1605-2420  9 2288 1919-2758 
Observer 10     32 2521 1942-3311  0 … …  12 2317 1891-3176  20 2652 2038-3314 
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Table S11.  Time-dependent DST and ST results by observer (continued from page 18).  Average values are geometric means [interquartile range (IR)]. 
[MRT=mean reaction time; DST=digit-symbol test; ST=Stroop test].   
Characteristica  
Overall    Baseline   Year 1   Year 2  
Nb Mean IR  Nb Mean IR  Nb Mean IR  Nb Mean IR 
MRT in congruent trials (ms, log)c                 
Observer 1      5 1238 1125-1428  5 1238 1125-1428  0 … …  0 … … 
Observer 2     5 1262 1103-1255  1 1255 …  4 1264 1084-1473  0 … … 
Observer 3     52 1343 1110-1567  49 1342 1119-1585  3 1362 1046-2084  0 … … 
Observer 4    31 1477 1173-1999  21 1280 1106-1467  10 1997 1894-2239  0 … … 
Observer 5    78 1610 1298-1859  40 1542 1276-1830  38 1685 1390—2078  0 … … 
Observer 6   39 1620 1246-1920  37 1644 1273-1920  2 1232 1062-1430  0 … … 
Observer 7    32 1824 1461-2198  0 … …  28 1814 1461-2198  4 1898 1639-2198 
Observer 8    87 1961 1570-2375  15 1925 1335-2327  63 1961 1598-2375  9 2026 1682-2844 
Observer 9    17 2173 1556-2827  0 … …  8 1907 1429-2384  9 2440 2057-2853 
Observer 10     32 2399 1680-3134  0 … …  12 2138 1646-2639  20 2571 1939-3189 
a Observers were sorted according to the participants’ performance in all neurocognitive test they took from the workers.  Braces join study nurses with similar mean 
latency time or MRT among the workers undergoing testing.  
b N indicates the number of tests.   
c Significance of the difference between observers derived by ANOVA: P<0.0001.   
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Table S12.  Geometric mean blood lead levels in the DST and ST cohorts by observer. [interquartile range (IR)]. [DST=digit-symbol test; ST=Stroop test].   
Characteristica   
Overall   Baseline   Year 1   Year 2  
Nb Mean IR  Nb Mean IR  Nb Mean IR  Nb Mean IR 
Blood lead in DST cohort (μg/dL, N=260)c                 
Observer 1     6 1.4 0.6-2.2  6 1.4 0.6-2.2  0 … …  0 … … 
Observer 2     72 4.2 2.6-7.2  69 3.9 2.6-6.5  3 13.6 7.1-24.5  0 … … 
Observer 3    57 4.3 2.8-7.7  53 4.0 2.5-7.3  2 14.5 12.1-17.4  2 10.9 5.0-23.7 
Observer 4     75 7.7 4.2-18.0  41 4.0 1.8-8.3  34 17.2 12.3-22.2  0 … … 
Observer 5    40 8.1 3.0-17.9  28 5.9 2.5-11.9  12 17.1 14.6-22.8  0 … … 
Observer 6   7 8.2 4.0-15.9  3 4.6 3.0-8.3  4 12.7 7.7-21.0  0 … … 
Observer 7   85 9.0 4.9-18.7  23 3.4 1.6-9.0  40 12.6 8.6-22.2  22 13.3 10.3-17.6 
Observer 8   148 9.6 5.2-18.6  37 3.8 2.0-7.2  70 13.1 8.6-20.6  41 13.0 11.7-19.4 
Observer 9   118 12.1 8.5-22.1  0 … …  40 13.2 10.6-22.6  78 11.6 7.4-21.8 
Observer 10    99 13.0 8.8-21.1  0 … …  39 11.3 7.8-19.5  60 14.2 11.1-21.9 
Blood lead in ST cohort (μg/dL, N=168)c                 
Observer 1     5 1.5 0.6-2.2  5 1.5 0.6-2.2  0 … …  0 … … 
Observer 2     52 3.9 2.6-6.4  49 3.6 2.6-5.7  3 13.6 7.1-24.5  0 … … 
Observer 3    39 4.4 2.8-8.3  37 4.1 2.8-7.3  2 14.5 12.1-17.4  0 … … 
Observer 4     31 8.4 3.7-15.9  21 6.0 2.9-11.8  10 16.7 14.7-23.1  0 … … 
Observer 5    78 8.4 4.3-19.1  40 4.2 1.8-8.7  38 17.7 12.9-23.9  0 … … 
Observer 6    87 11.1 6.8-19.2  15 5.0 3.2-10.0  63 13.4 8.3-20.6  9 11.7 11.0-14.8 
Observer 7   5 11.7 8.3-15.9  1 8.3 …  4 12.7 7.7-21.0  0 … … 
Observer 8   32 12.2 9.4-19.9  0 … …  28 12.2 9.4-19.9  4 11.9 7.7-18.3 
Observer 9    17 16.6 14.1-20.4  0 … …  8 14.1 12.4-16.5  9 19.1 15.9-24.6 
Observer 10    32 17.3 14.8-24.5  0 … …  12 15.6 15.1-23.8  20 18.3 14.8-25.3 
a Observers were sorted according to the participants’ baseline blood lead concentration.  Braces join study nurses with similar blood lead levels in tested workers.  
b N indicates the number of tests.   
c Significance of the difference between observers derived by ANOVA: P<0.0001.   





Figure S1  
Bland–Altman plot for duplicate blood lead measurements in 30 workers.  
The difference between both measurements was plotted against the 
average of both measurements.  The bias (repeat minus first measurement) 
was +0.08 µg/dL (P=0.078).  The reproducibility coefficient (RC) is twice the 
SD of the signed differences between duplicate measurements.  
Reproduced from reference 17.   





Figure S2  
Baseline age distribution in the DST [A] and ST [B] cohorts. [M, 
mean; S, skewness; K, kurtosis; DST=digit-symbol test; ST=Stroop 
test].   The solid and dotted lines represent the normal and kernel 
density distributions.  The P values are for departure of the actually 
observed distribution from normality according to the Shapiro-Wilk 
statistic.   





Figure S3  
Blood lead levels at baseline and at the 1-year and 2-year follow-up visits in 
189 workers with 2 follow-up visits.  Plotted values are geometric means.  
Vertical bars indicate the interquatile range.   





Figure S4  
Distributions of baseline blood lead, follow-up blood lead, and the baseline-to-last-follow-up ratios in blood lead in the DST and ST 
cohorts. [M, mean; S, skewness; K, kurtosis; DST=digit-symbol test; ST=Stroop test; BL=blood lead].  The solid and dotted lines 
represent the normal and kernel density distributions.  The P values are for departure of the actually observed distribution from 
normality according to the Shapiro-Wilk statistic.   






Figure S5  
Associations of the changes from baseline to last follow-up (∆) in latency time in DST cohort and in mean reaction time in ST 
cohort with the follow-up-to-baseline blood lead concentration ratio (∆). [DST=digit-symbol test; ST=Stroop test].  Closed and 
open symbols depict the first and second follow-up results, respectively.  The regression line with 95% confidence interval were 
derived from mixed models accounting for clustering of the observations within participants.  Adjusted models accounted for sex, 
baseline age and the baseline value of latency time or mean reaction time.  Fully adjusted models additionally accounted for for 
ethnicity (white vs other), change in age, baseline body mass index, changes in body weight, educational attainment, baseline 
blood lead, and the baseline values of and changes during follow-up in smoking status, and the total-to-HDL serum cholesterol 
ratio and alcohol consumption (light, moderate and heavy drinkers).   
